Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D. Engstrom(Mirati Therapeutics (United States)), James G. Christensen, Carrie R. Graveel(Van Andel Institute), David M. Briere(Mirati Therapeutics (United States)), Darya Chudova(Guardant (United States)), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Ruth Aranda(Mirati Therapeutics (United States)), Zachary Madaj(Van Andel Institute), Nir Peled(Shaare Zedek Medical Center), Lyudmila Bazhenova(Memorial Sloan Kettering Cancer Center), Peter Olson(RIKEN BioResource Research Center), Geoffrey I. Shapiro(Brigham and Women's Hospital), Pasi A. Jänne(Harvard University), Camino Menéndez(Spanish National Cancer Research Centre), Curt J. Essenburg(Van Andel Institute), Vanessa Tassell(Pfizer (United States)), Harrah Chiang(Mirati Therapeutics (United States)), Mizuki Nishino(Brigham and Women's Hospital), Sandip Pravin Patel(University of California San Diego), Pedro P. López‐Casas(Spanish National Cancer Research Centre), Richard C. Chao(Mirati Therapeutics (United States)), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Manuel Hidalgo(Hospital Universitario de Fuenlabrada), Natalia Baños(Spanish National Cancer Research Centre), Elizabeth A. Tovar(Van Andel Institute), Matthew Lee(The Ohio State University), Jill Hallin(Bristol-Myers Squibb (United States))
Cited by 147
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k